Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treo-Ped-1 treosulfan-based conditioning in pediatric allogeneic HSCT (Japan)
jRCT2051250222Phase 1Not yet recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of treosulfan in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 6 more (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Dose-limiting toxicity (DLT). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
treosulfan
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)lymphomachronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2051250222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250222.